ClinicalTrials.Veeva

Menu

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

University of Pittsburgh logo

University of Pittsburgh

Status and phase

Withdrawn
Phase 4

Conditions

Gestational Diabetes

Treatments

Drug: Glyburide
Device: Continuous glucose monitor

Study type

Interventional

Funder types

Other

Identifiers

NCT01947699
UPMC_GLY_GDM

Details and patient eligibility

About

Diabetes is more likely to occur during pregnancy. When present only in pregnancy it is called gestational diabetes, and it places both mom and baby at risk for complications. Glyburide is one of the currently used treatments for diabetes during pregnancy. This drug is a medication taken by mouth that decreases sugar levels in the blood. It is known to decrease the risk of complications linked to diabetes in pregnancy. Recent studies in pregnancy have described a difference in the way and how well the drug works compared to when used outside of pregnancy.

Oral blood sugar lowering agents are approved by the Food and Drug Administration (FDA) to lower blood sugar in non-pregnant subjects with diabetes. No oral (taken by mouth) blood-sugar lowering agents are FDA approved for use in pregnancy. Although Glyburide is not FDA approved for this use, it is the most commonly used oral blood sugar lowering agent in pregnancy.

This research study will help us learn more about the variations in blood sugar levels in women with diabetes in pregnancy who are taking glyburide and how changes in the timing of when the glyburide is taken would affect blood glucose levels. The goals of this study are:

  • To find the how glucose changes throughout the day in women with diabetes in pregnancy receiving glyburide
  • To learn the effect of changing the time of taking glyburide on glucose levels
  • To learn the effect of changing the time between glyburide doses on glucose levels
  • To see if insulin is secreted the same throughout the day in response to a morning dose of glyburide.

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pregnant women with gestational diabetes
  • Singleton gestation
  • Receiving glyburide for the treatment gestational diabetes
  • Able to give consent

Exclusion criteria

  • Women who require insulin for the treatment of gestational diabetes
  • Diagnosis of pregestational diabetes
  • Poor glycemic control, > 50% of blood glucose values over 200mg/dl prior to start of the study
  • Women receiving medications that affect glycemic control e.g. steroids, within a week of enrollment.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 3 patient groups

Glyburide once daily
Experimental group
Description:
Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
Treatment:
Device: Continuous glucose monitor
Drug: Glyburide
Glyburide twice daily
Experimental group
Description:
Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
Treatment:
Device: Continuous glucose monitor
Drug: Glyburide
Mixed meal tolerance test.
Experimental group
Description:
Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
Treatment:
Drug: Glyburide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems